Pruritogenic Mediators and New Antipruritic Drugs in Atopic Dermatitis.

J Clin Med · 2023 · PMC10054239 · PMID 36983094

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

When compared to placebo with TCS, patients receiving tezepelumab showed marginally significant improvements in pruritus numeric rating scale (NRS) from baseline to week 12 ( Table 2 ) [ 80 ]. 3.3.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.